CTS™ AIM V™ SFM
CTS™ AIM V™ SFM
Citas y referencias (31)
Gibco™

CTS™ AIM V™ SFM

SFM CTS AIM V Gibco (calidad terapéutica) es el primer medio sin suero (SFM) disponible comercialmente para la el proliferaciónMás información
Have Questions?
Cambiar vistabuttonViewtableView
Número de catálogoCantidad
0870112DK1000 mL
0870112BK10 L
Número de catálogo 0870112DK
Precio (MXN)
5,316.32
Each
Añadir al carro de la compra
Cantidad:
1000 mL
Precio (MXN)
5,316.32
Each
Añadir al carro de la compra
SFM CTS AIM V Gibco (calidad terapéutica) es el primer medio sin suero (SFM) disponible comercialmente para la el proliferación y/o manipulación de células T y células dendríticas, y fabricado según las buenas prácticas de fabricación actuales. Contiene L-glutamina, sulfato de estreptomicina a 50 µg/ml y sulfato de gentamicina a 10 µg/m.
Diseñado para aplicaciones de procesamiento de cultivos celulares y de tejido ex vivo.PRECAUCIÓN:Cuando se utiliza como dispositivo médico, la ley federal restringe su venta a los médicos o por orden de estos.
Especificaciones
Tipo de célulaMonocitos, células dendríticas, células T, hibridomas, PBMC, fibroblastos, macrófagos, células de mieloma, linfocitos
Para utilizar con (aplicación)Investigación de terapias con células
FormatoFrasco
Calidad de fabricaciónISO 13485, MDSAP, FDA-registered, 21 CFR 820
Tipo de productoMedio sin suero (SFM)
Cantidad1000 mL
Duración de almacenamiento14 meses
Condiciones de envíoAmbiente
ClasificaciónSin suero
FormularioLíquido
Serum LevelSin suero
EsterilidadEstéril con filtro
Unit SizeEach
Contenido y almacenamiento
Almacenar el medio entre 2 y 8°C. Proteja el producto de la luz. AIM V™ tiene una vida útil de 14 meses.

Preguntas frecuentes

What is CTS?

The Gibco Cell Therapy Systems (CTS) portfolio of cell and gene therapy products are GMP manufactured, safety tested, and backed by regulatory documentation to support your transition from discovery through clinical and commercial manufacturing. Through our CTS solutions, we are committed to helping customers streamline therapeutic development, minimize risk, and ease the burden on their quality systems. Learn more here.

Find additional tips, troubleshooting help, and resources within our Cell Culture Support Center.

What is the difference between AIM V Medium (Cat. Nos. 12055083, 12055091) and CTS AIM V SFM (Cat. Nos. 0870112DK, 0870112BK)?

The difference is in the intended usage of the two media. AIM V Medium (Cat. Nos. 12055083, 12055091) is for research use only whereas CTS AIM V SFM (Cat. Nos. 0870112DK, 0870112BK) is for research use or manufacturing of cell, gene, or tissue-based products.

Find additional tips, troubleshooting help, and resources within our Cell Culture Support Center.

What is the difference between CTS AIM-V Medium and CTS AIM V SFM?

These two media have comparable performance and same cGMP quality. The main difference is that CTS AIM-V Medium (Cat. Nos. A3830801, A3830802, A4672701) does not contain phenol red and antibiotics. This medium formulation has been used as an ancillary reagent in a therapeutic cancer vaccine approved by FDA.

Find additional tips, troubleshooting help, and resources within our Cell Culture Support Center.

Citations & References (31)

Citations & References
Abstract
Live attenuated lentivirus infection elicits polyfunctional simian immunodeficiency virus Gag-specific CD8+ T cells with reduced apoptotic susceptibility in rhesus macaques that control virus replication after challenge with pathogenic SIVmac239.
Authors:Genescà M, Rourke T, Li J, Bost K, Chohan B, McChesney MB, Miller CJ,
Journal:J Immunol
PubMed ID:17878372
'HIV-specific CD8+ T cells that secrete multiple cytokines in response to Ag stimulation are associated with the control of virus replication during chronic HIV infection. To determine whether the presence of polyfunctional CD8+ T cell responses distinguishes protected and unprotected monkeys in a live attenuated lentivirus model, SIV Gag peptide-specific ... More
Performance of serum-supplemented and serum-free media in IFNgamma Elispot Assays for human T cells.
Authors:Janetzki S, Price L, Britten CM, van der Burg SH, Caterini J, Currier JR, Ferrari G, Gouttefangeas C, Hayes P, Kaempgen E, Lennerz V, Nihlmark K, Souza V, Hoos A,
Journal:Cancer Immunol Immunother
PubMed ID:19894047
'The choice of serum for supplementation of media for T cell assays and in particular, Elispot has been a major challenge for assay performance, standardization, optimization, and reproducibility. The Assay Working Group of the Cancer Vaccine Consortium (CVC-CRI) has recently identified the choice of serum to be the leading cause ... More
[Study of adoptive immunotherapy for metastatic renal cell carcinoma with lymphokine-activated killer (LAK) cells and interleukin-2. II. Clinical evaluation]
Authors:Nomura K, Fujioka T,
Journal:Nippon Hinyokika Gakkai Zasshi
PubMed ID:8320888
'We evaluated adoptive immunotherapy using LAK cells combined with systemic administration of interleukin-2 (IL-2) in 11 patients with metastatic renal cell carcinoma. The LAK cells were generated by incubation in serum-free medium (AIM-V) supplemented with IL-2 (1,000 U/ml) for 4 days and were generally administered twice weekly (4 times/cycle). Daily ... More
Serum-free culture medium and IL-7 costimulation increase the sensitivity of ELISpot detection.
Authors:Martinuzzi E, Scotto M, Enée E, Brezar V, Ribeil JA, van Endert P, Mallone R
Journal:J Immunol Methods
PubMed ID:18242633
'The identification of parameters maximizing detection sensitivity in ELISpot assays is important to transfer this technology into the clinical setting for identifying rare Ag-specific CD8(+) T cells. We have therefore considered human IFN-gamma CD8(+) T cell responses against viral epitopes to analyze different variables which could be critical during the ... More
CD4 T cells guarantee optimal competitive fitness of CD8 memory T cells.
Authors:Johansen P, Stamou P, Tascon RE, Lowrie DB, Stockinger B,
Journal:Eur J Immunol
PubMed ID:14971034
We studied the contribution of CD4 T cell help to survival and competitive fitness of CD8 memory T cells specific for influenza virus nucleoprotein. In agreement with recent studies, the optimal generation of functional memory CD8 T cells required CD4 help, although long-term maintenance of resting CD8 memory T cells ... More
View all CTS™ AIM V™ SFM citations